(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are PETROLIA, REDITUS,SGPS, and BIOSENIC.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| PETROLIA (PSE.OL) | 4.94 | 20.19% | 2023-09-26 12:42:33 |
| REDITUS,SGPS (RED.LS) | 0.07 | 16.67% | 2023-09-26 12:24:26 |
| BIOSENIC (BIOS.BR) | 0.12 | 12.68% | 2023-09-26 12:06:05 |
| NEW SOURCES ENERGY (NSE.AS) | 0.04 | 6.06% | 2023-09-26 12:03:30 |
| MOURY CONSTRUCT (MOUR.BR) | 392.00 | 5.95% | 2023-09-26 12:21:02 |
| MOREFIELD GROUP (MORE.AS) | 0.33 | 5.77% | 2023-09-26 12:03:19 |
| GENTIAN DIAGNOSTIC (GENT.OL) | 43.00 | 4.88% | 2023-09-26 12:40:13 |
| MKB Nedsense (NEDSE.AS) | 0.11 | 4.81% | 2023-09-26 12:03:16 |
| AKWEL (AKW.PA) | 15.90 | 4.61% | 2023-09-26 12:46:06 |
| HØLAND OG SETSKOG (HSPG.OL) | 130.00 | 4% | 2023-09-26 12:40:42 |
The three biggest losers today are NORTHERN DRILLING, ATENOR, and MITHRA.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| NORTHERN DRILLING (NODL.OL) | 3.86 | -85.96% | 2023-09-26 12:41:54 |
| ATENOR (ATEB.BR) | 12.90 | -15.96% | 2023-09-26 12:05:35 |
| MITHRA (MITRA.BR) | 1.79 | -14.04% | 2023-09-26 12:20:51 |
| CELYAD ONCOLOGY (CYAD.BR) | 0.67 | -11.61% | 2023-09-26 12:06:20 |
| NEL (NEL.OL) | 8.21 | -10.35% | 2023-09-26 12:41:40 |
| PCI BIOTECH HOLD (PCIB.OL) | 1.46 | -7.49% | 2023-09-26 12:42:31 |
| SAS AB (SASNO.OL) | 0.27 | -6.86% | 2023-09-26 12:43:15 |
| ATLAND (ATLD.PA) | 34.40 | -6.52% | 2023-09-26 12:46:50 |
| ADOCIA (ADOC.PA) | 6.45 | -6.52% | 2023-09-26 12:45:44 |
| PHOTOCURE (PHO.OL) | 57.80 | -6.32% | 2023-09-26 12:42:42 |
Winners today
1. PETROLIA (PSE.OL)
20.19% Price Change
Petrolia SE, together with its subsidiaries, sells and rents energy service equipment to energy industry in Norway, rest of Europe, Asia, and Australia. It operates through two segments, Energy and Energy Service. The company engages in the exploration and production of oil and gas, as well as produces hydrogen and ammonia. It also offers drill pipes, test strings and tubing, and other equipment, as well as casing, handling, and auxiliary tools; and equipment inspection and maintenance services. In addition, the company offers casing and tubing running, drilling, and make and brake services. It serves energy companies, drilling contractors, and energy service companies. The company was formerly known as Petrolia E&P Holdings SE and changed its name to Petrolia SE in January 2013. Petrolia SE was founded in 1997 and is based in Limassol, Cyprus.
Oslo Børs Benchmark Index_GI ended the session with PETROLIA jumping 20.19% to €4.94 on Tuesday while Oslo Børs Benchmark Index_GI dropped 0.36% to €1,278.97.
Earnings Per Share
As for profitability, PETROLIA has a trailing twelve months EPS of kr0.04.
PE Ratio
PETROLIA has a trailing twelve months price to earnings ratio of 123.5. Meaning, the purchaser of the share is investing kr123.5 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.94%.
Yearly Top and Bottom Value
PETROLIA’s stock is valued at kr4.94 at 22:40 EST, below its 52-week high of kr5.28 and way above its 52-week low of kr3.48.
More news about PETROLIA.
2. REDITUS,SGPS (RED.LS)
16.67% Price Change
Reditus, Sociedade Gestora de Participações Sociais, S.A., through its subsidiaries, provides business process outsourcing, IT outsourcing, and IT consulting services in Portugal and internationally. The company offers client services, including client, financial, human resource, doc, and facilities management, as well as other business process services; and IT infrastructure services and solutions in the areas of advisory, design, installation, and maintenance of systems and solutions, storage, network, and security. It also provides specialized outsourcing services in the areas of application development and maintenance, DBs and system administration, business intelligence and applications, telecom engineering and networks, and support and helpdesk; and information security services and solutions, as well as security managed services. In addition, the company offers enterprise content management services, solutions, and products for deployment of projects in scanning, document management, and workflow in multi-channel topologies; lean management services and solutions in practical application of diagnostic methodologies; and management and IT consulting services and solutions. Further, it is involved in the development, management, and maintenance of software applications and analytical solutions; and provision of cooperation and development services and solutions in the areas of corporate procurement, project management, and economic and social development, as well as training and personal development services. The company serves public, health, telecom, media, utilities, financial services, consumer, retail, and transportation sectors. The company was founded in 1966 and is headquartered in Lisbon, Portugal.
PSI ended the session with REDITUS,SGPS rising 16.67% to €0.07 on Tuesday, following the last session’s upward trend. PSI fell 0.29% to €6,101.58, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, REDITUS,SGPS has a trailing twelve months EPS of €0.22.
PE Ratio
REDITUS,SGPS has a trailing twelve months price to earnings ratio of 0.32. Meaning, the purchaser of the share is investing €0.32 for every euro of annual earnings.
Volume
Today’s last reported volume for REDITUS,SGPS is 2500 which is 86.14% below its average volume of 18043.
Volatility
REDITUS,SGPS’s last week, last month’s, and last quarter’s current intraday variation average was 15.56%, 5.61%, and 10.56%.
REDITUS,SGPS’s highest amplitude of average volatility was 15.56% (last week), 8.95% (last month), and 10.56% (last quarter).
More news about REDITUS,SGPS.
3. BIOSENIC (BIOS.BR)
12.68% Price Change
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with BIOSENIC jumping 12.68% to €0.12 on Tuesday while BEL 20 slid 1.14% to €3,539.81.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.01.
Volume
Today’s last reported volume for BIOSENIC is 1442560 which is 46.24% above its average volume of 986411.
More news about BIOSENIC.
4. NEW SOURCES ENERGY (NSE.AS)
6.06% Price Change
New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.
AEX-Index ended the session with NEW SOURCES ENERGY rising 6.06% to €0.04 on Tuesday, following the last session’s downward trend. AEX-Index fell 0.72% to €721.43, after three consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session today.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -288.52%.
Moving Average
NEW SOURCES ENERGY’s value is way above its 50-day moving average of €0.02 and way under its 200-day moving average of €0.05.
Volatility
NEW SOURCES ENERGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 7.19%, a negative 0.62%, and a positive 13.10%.
NEW SOURCES ENERGY’s highest amplitude of average volatility was 9.28% (last week), 13.37% (last month), and 13.10% (last quarter).
Yearly Top and Bottom Value
NEW SOURCES ENERGY’s stock is valued at €0.04 at 22:40 EST, way under its 52-week high of €0.07 and way above its 52-week low of €0.01.
More news about NEW SOURCES ENERGY.
5. MOURY CONSTRUCT (MOUR.BR)
5.95% Price Change
Moury Construct SA engages in the construction and renovation of residential and non-residential buildings for private and public markets in Belgium. The company constructs public and private buildings, commercial areas, halls of structures, renovation and restoration, and industries and services projects. It is also involved in the general carpentry, thermal, and acoustic insulations; prefabrication of concrete elements; and promotion and real estate arrangements. Moury Construct SA was founded in 1920 and is based in Liège, Belgium.
BEL 20 ended the session with MOURY CONSTRUCT jumping 5.95% to €392.00 on Tuesday, after five sequential sessions in a row of losses. BEL 20 dropped 1.14% to €3,539.81, after three successive sessions in a row of losses, on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, MOURY CONSTRUCT has a trailing twelve months EPS of €43.84.
PE Ratio
MOURY CONSTRUCT has a trailing twelve months price to earnings ratio of 8.94. Meaning, the purchaser of the share is investing €8.94 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.61%.
Volume
Today’s last reported volume for MOURY CONSTRUCT is 496 which is 740.67% above its average volume of 59.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 15, 2023, the estimated forward annual dividend rate is 9.7 and the estimated forward annual dividend yield is 2.59%.
More news about MOURY CONSTRUCT.
6. MOREFIELD GROUP (MORE.AS)
5.77% Price Change
Morefield Group N.V. through its subsidiary Kersten Groep BV, engages in the selecting, advising, supplying, and maintaining medical aids for physical disability peoples. The company manufactures orthoses, such as braces and splints. It serves to municipalities, care administration offices, health insurers, and care institutions/care organizations. The company was formerly known as HeadFirst Source Group N.V. and changed its name to Morefield Group N.V. in January 2019. Morefield Group N.V. was incorporated in 1983 and is headquartered in Willemstad, Curaçao.
AEX-Index ended the session with MOREFIELD GROUP jumping 5.77% to €0.33 on Tuesday, following the last session’s downward trend. AEX-Index slid 0.72% to €721.43, after three sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, MOREFIELD GROUP has a trailing twelve months EPS of €0.1.
PE Ratio
MOREFIELD GROUP has a trailing twelve months price to earnings ratio of 3.3. Meaning, the purchaser of the share is investing €3.3 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.06%.
Moving Average
MOREFIELD GROUP’s worth is higher than its 50-day moving average of €0.31 and higher than its 200-day moving average of €0.30.
Yearly Top and Bottom Value
MOREFIELD GROUP’s stock is valued at €0.33 at 22:40 EST, way below its 52-week high of €0.38 and way above its 52-week low of €0.27.
Volume
Today’s last reported volume for MOREFIELD GROUP is 10 which is 99.9% below its average volume of 10083.
More news about MOREFIELD GROUP.
7. GENTIAN DIAGNOSTIC (GENT.OL)
4.88% Price Change
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. Gentian Diagnostics ASA was incorporated in 2001 and is headquartered in Moss, Norway.
Oslo Børs Benchmark Index_GI ended the session with GENTIAN DIAGNOSTIC rising 4.88% to €43.00 on Tuesday, after four consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.36% to €1,278.97, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, GENTIAN DIAGNOSTIC has a trailing twelve months EPS of kr-0.86.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.53%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENTIAN DIAGNOSTIC’s stock is considered to be overbought (>=80).
Moving Average
GENTIAN DIAGNOSTIC’s value is under its 50-day moving average of kr44.63 and below its 200-day moving average of kr43.19.
More news about GENTIAN DIAGNOSTIC.
8. MKB Nedsense (NEDSE.AS)
4.81% Price Change
MKB Nedsense N.V. engages in the finance and lending of money to natural persons and legal entities. It also provides guarantees and/or other securities towards third parties for its obligations and/or for obligations for companies in the investment portfolio. The company was formerly known as Nedsense Enterprises N.V. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands.
AEX-Index ended the session with MKB Nedsense jumping 4.81% to €0.11 on Tuesday, following the last session’s downward trend. AEX-Index fell 0.72% to €721.43, after three sequential sessions in a row of losses, on what was a somewhat bearish trend trading session today.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.03%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MKB Nedsense’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for MKB Nedsense is 5100 which is 47.96% below its average volume of 9801.
Moving Average
MKB Nedsense’s value is above its 50-day moving average of €0.11 and below its 200-day moving average of €0.12.
Volatility
MKB Nedsense’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.47%, a negative 0.21%, and a positive 3.44%.
MKB Nedsense’s highest amplitude of average volatility was 3.29% (last week), 2.79% (last month), and 3.44% (last quarter).
More news about MKB Nedsense.
9. AKWEL (AKW.PA)
4.61% Price Change
Akwel SA manufactures automotive and heavy goods vehicle components in France and internationally. It offers fluid management, mechanisms, and structural parts for electric vehicles. The company's products include body pipes, flow regulation valves, anti-return valves, pulsation dampeners or temperature, and pressure sensors; air distributors, turbo air intake and output pipes and exchangers, exhaust gas recirculation pipes, and cylinder head covers, as well as a range of solutions for cooling and combining. It also offers electronic management of hardware, software, transfer, storage, reheating, and pumping systems; and manages washer systems, including storage, pumping, transfer, and jet. The company was formerly known as MGI Coutier SA and changed its name to AKWEL in June 2018. The company was founded in 1972 and is based in Champfromier, France. Akwel SA operates as a subsidiary of Coutier Junior Company.
CAC 40 ended the session with AKWEL jumping 4.61% to €15.90 on Tuesday while CAC 40 fell 0.7% to €7,074.02.
Earnings Per Share
As for profitability, AKWEL has a trailing twelve months EPS of €0.41.
PE Ratio
AKWEL has a trailing twelve months price to earnings ratio of 38.78. Meaning, the purchaser of the share is investing €38.78 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.9%.
Moving Average
AKWEL’s value is way above its 50-day moving average of €13.88 and higher than its 200-day moving average of €15.01.
More news about AKWEL.
10. HØLAND OG SETSKOG (HSPG.OL)
4% Price Change
Høland og Setskog Sparebank provides banking services for the retail and corporate markets in Norway. It offers deposits and loans, as well as insurance products. The company was formerly known as Holand Sparebank and changed its name to Høland og Setskog Sparebank in 2010. The company was founded in 1849 and is headquartered in Bjørkelangen, Norway.
Oslo Børs Benchmark Index_GI ended the session with HØLAND OG SETSKOG jumping 4% to €130.00 on Tuesday while Oslo Børs Benchmark Index_GI slid 0.36% to €1,278.97.
Earnings Per Share
As for profitability, HØLAND OG SETSKOG has a trailing twelve months EPS of kr8.6.
PE Ratio
HØLAND OG SETSKOG has a trailing twelve months price to earnings ratio of 15.12. Meaning, the purchaser of the share is investing kr15.12 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
More news about HØLAND OG SETSKOG.
Losers Today
1. NORTHERN DRILLING (NODL.OL)
-85.96% Price Change
Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.
Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING sliding 85.96% to €3.86 on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0.36% to €1,278.97, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-6.01.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.
More news about NORTHERN DRILLING.
2. ATENOR (ATEB.BR)
-15.96% Price Change
Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.
BEL 20 ended the session with ATENOR sliding 15.96% to €12.90 on Tuesday, after two successive sessions in a row of losses. BEL 20 fell 1.14% to €3,539.81, after three sequential sessions in a row of losses, on what was an all-around down trend exchanging session today.
Earnings Per Share
As for profitability, ATENOR has a trailing twelve months EPS of €-9.45.
More news about ATENOR.
3. MITHRA (MITRA.BR)
-14.04% Price Change
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
BEL 20 ended the session with MITHRA sliding 14.04% to €1.79 on Tuesday while BEL 20 dropped 1.14% to €3,539.81.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-1.3.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -176.58%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 428.6%, now sitting on 67M for the twelve trailing months.
Yearly Top and Bottom Value
MITHRA’s stock is valued at €1.79 at 22:40 EST, way below its 52-week high of €6.87 and way higher than its 52-week low of €1.25.
Volume
Today’s last reported volume for MITHRA is 502415 which is 66.8% above its average volume of 301205.
Volatility
MITHRA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.61%, a negative 0.39%, and a positive 4.94%.
MITHRA’s highest amplitude of average volatility was 3.13% (last week), 2.90% (last month), and 4.94% (last quarter).
More news about MITHRA.
4. CELYAD ONCOLOGY (CYAD.BR)
-11.61% Price Change
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with CELYAD ONCOLOGY sliding 11.61% to €0.67 on Tuesday while BEL 20 slid 1.14% to €3,539.81.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.25.
Volatility
CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.90%, a positive 2.01%, and a positive 5.23%.
CELYAD ONCOLOGY’s highest amplitude of average volatility was 4.08% (last week), 10.57% (last month), and 5.23% (last quarter).
More news about CELYAD ONCOLOGY.
5. NEL (NEL.OL)
-10.35% Price Change
Nel ASA, a hydrogen company, provides various solutions to produce, store, and distribute hydrogen from renewable energy in Norway and internationally. The company operates in two segments, Nel Hydrogen Fueling and Nel Hydrogen Electrolyser. The Nel Hydrogen Fueling segment produces H2Station hydrogen fueling stations that provide fuel cell electric vehicles with the fueling and long range as conventional fossil fuel vehicles, include cars, buses, trucks, and other applications. The Nel Hydrogen Electrolyser segment supplies hydrogen production equipment based on alkaline and proton exchange membrane water electrolysis technology. It serves industry, energy, and gas companies. The company was formerly known as DiaGenic ASA and changed its name to Nel ASA in October 2014. Nel ASA was founded in 1927 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with NEL dropping 10.35% to €8.21 on Tuesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI dropped 0.36% to €1,278.97, following the last session’s downward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, NEL has a trailing twelve months EPS of kr-0.96.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.44%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NEL’s EBITDA is 9.29.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 41.2% and 80.4%, respectively.
Moving Average
NEL’s worth is way under its 50-day moving average of kr11.99 and way under its 200-day moving average of kr13.97.
More news about NEL.
6. PCI BIOTECH HOLD (PCIB.OL)
-7.49% Price Change
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD falling 7.49% to €1.46 on Tuesday while Oslo Børs Benchmark Index_GI fell 0.36% to €1,278.97.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.
Volume
Today’s last reported volume for PCI BIOTECH HOLD is 123424 which is 15.11% below its average volume of 145399.
Revenue Growth
Year-on-year quarterly revenue growth declined by 84.4%, now sitting on 2.79M for the twelve trailing months.
More news about PCI BIOTECH HOLD.
7. SAS AB (SASNO.OL)
-6.86% Price Change
SAS AB (publ), together with its subsidiaries, provides passenger flight transportation services in the Nordic and international route network. The company also offers air cargo services, in-flight sales, ground handling, and technical maintenance services, as well as travel-related loyalty programs. It operates a fleet of 135 aircraft, including 12 long-haul aircraft, 95 short-haul aircraft, and 28 aircraft flown by regional production partners. The company was founded in 1946 and is headquartered in Stockholm, Sweden. On July 5, 2022, SAS AB (publ), along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Oslo Børs Benchmark Index_GI ended the session with SAS AB falling 6.86% to €0.27 on Tuesday while Oslo Børs Benchmark Index_GI slid 0.36% to €1,278.97.
Earnings Per Share
As for profitability, SAS AB has a trailing twelve months EPS of kr-0.66.
Volume
Today’s last reported volume for SAS AB is 8406280 which is 216.8% above its average volume of 2653440.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SAS AB’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
SAS AB’s stock is valued at kr0.27 at 22:40 EST, way under its 52-week high of kr0.71 and way higher than its 52-week low of kr0.20.
Volatility
SAS AB’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.06%, a negative 0.68%, and a positive 1.48%.
SAS AB’s highest amplitude of average volatility was 2.23% (last week), 1.82% (last month), and 1.48% (last quarter).
More news about SAS AB.
8. ATLAND (ATLD.PA)
-6.52% Price Change
Fonciere Atland operates as a real estate investment trust. It invests in offices, retail outlets, warehouses, or light industrial premises. It also provides real estate sale-leaseback services, and construction and turnkey rental development services to business customers. The company is based in Paris, France.
CAC 40 ended the session with ATLAND sliding 6.52% to €34.40 on Tuesday, following the last session’s upward trend. CAC 40 fell 0.7% to €7,074.02, after three sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, ATLAND has a trailing twelve months EPS of €1.53.
PE Ratio
ATLAND has a trailing twelve months price to earnings ratio of 22.48. Meaning, the purchaser of the share is investing €22.48 for every euro of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATLAND’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for ATLAND is 1085 which is 115.27% above its average volume of 504.
More news about ATLAND.
9. ADOCIA (ADOC.PA)
-6.52% Price Change
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
CAC 40 ended the session with ADOCIA dropping 6.52% to €6.45 on Tuesday while CAC 40 fell 0.7% to €7,074.02.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-2.31.
Yearly Top and Bottom Value
ADOCIA’s stock is valued at €6.45 at 22:40 EST, under its 52-week high of €6.62 and way above its 52-week low of €2.74.
More news about ADOCIA.
10. PHOTOCURE (PHO.OL)
-6.32% Price Change
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with PHOTOCURE falling 6.32% to €57.80 on Tuesday, after two successive sessions in a row of gains. Oslo Børs Benchmark Index_GI dropped 0.36% to €1,278.97, following the last session’s downward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, PHOTOCURE has a trailing twelve months EPS of kr-1.44.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.24%.
Sales Growth
PHOTOCURE’s sales growth for the next quarter is 12%.
More news about PHOTOCURE.
Stay up to date with our winners and losers daily report
